National Investment and Infrastructure Fund
- National Investment and Infrastructure Fund, is an Indian-government backed entity established to provide long-term capital to the country’s infrastructure sector.
- The Indian government has 49 per cent stake in NIIF with the rest held by marquee foreign and domestic investors such as Abu Dhabi Investment Authority, Temasek and HDFC Group. With the Centre’s significant stake, NIIF is considered India’s quasi sovereign wealth fund.
- It has three funds
- Master Fund: The Master Fund is an infrastructure fund focuses mainly on core infrastructure and operating assets
- Fund of Funds: NIIF Fund of Funds invests in funds managed by third-party managers in the infrastructure and associated sectors
- Strategic Investment Fund: The objective of National Investment and Infrastructure Fund II (“Strategic Fund”) is to invest largely in equity and equity-linked instruments. The Strategic Fund will focus on green field and brown field investments in the core infrastructure sectors.
DGCA
- The Directorate General of Civil Aviation (DGCA) is the regulatory body in the field of Civil Aviation, primarily dealing with safety issues. It is responsible for regulation of air transport services to/from/within India and for enforcement of civil air regulations, air safety, and airworthiness standards. The DGCA also co-ordinates all regulatory functions with the International Civil Aviation Organisation (ICAO).
CAR – T Cell therapy
- Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells.
- In CAR T-cell therapies, T cells are taken from the patient’s blood and are changed in the lab by adding a gene for a receptor (called a chimeric antigen receptor or CAR), which helps the T cells attach to a specific cancer cell antigen. The CAR T cells are then given back to the patient.
- Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. CAR T-cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer. Also called chimeric antigen receptor T-cell therapy.